Natalizumab treatment associated with reduction of gliotic biomarkers in white matter

3067 2300 Michael Furrer, PhD

New data on the effect of natalizumab treatment on neuronal and membrane integrity in lesional white matter were presented at the recent 5th Annual Congress of the European Academy of…

read more

Serum NfL levels shine a light on neuroaxonal damage and disease

4089 2300 Michael Furrer, PhD

The 5th Annual Congress of the European Academy of Neurology (EAN) in Oslo, Norway, featured an in-depth exploration of the role of neurofilament light chain (NfL) protein levels as a…

read more

Cellular power failures linked to Parkinsonism

3150 2100 Mea Holm, PhD

Mounting evidence is linking neurodegenerative disorders, such as Parkinsonism and dementia, with mitochondrial dysfunction.1 At the 5th Annual Congress of the European Academy of Neurology (EAN) in Oslo, Norway, the…

read more

8-year follow-up data of alemtuzumab presented

1920 1280 Michael Furrer, PhD

An update of the long-term efficacy and safety data of alemtuzumab in patients with relapsing-remitting MS was presented at the 5th Annual Congress of the European Academy of Neurology (EAN)…

read more

Thought-controlled prosthetic limbs could be in reach

3446 2300 Peter Stevenson, PhD

Improvements in the way in which neural activity is mapped could be an important step towards thought-controlled body augmentations such as prosthetic limbs, researchers at the Neural Prosthetics Translational Laboratory…

read more
man speaking

Machine-learning algorithm predicts psychosis from speech

3150 2100 Peter Stevenson, PhD

Algorithms designed to find hidden clues within everyday language can predict those at risk of developing psychosis, a new study reports. Using machine learning, researchers from the Department of Psychology…

read more

Shedding light on CIDP

1920 1080 Carlotta Foletti, PhD

While it is the most common chronic autoimmune neuropathy, chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare, acquired peripheral neuropathy characterised by proximal upper and lower limb weakness. CIDP remains…

read more

Establishing sNfL as an MS Biomarker

3300 2200 Carlotta Foletti, PhD

At the ECTRIMS annual congress in October 2018, there was a lot of talk on serum neurofilament light (sNfL) becoming the first blood biomarker predicting neuronal damage caused by neurological…

read more

News from the ocrelizumab front

3300 2200 Carlotta Foletti, PhD

In our ongoing coverage of the AAN Annual Meeting in Philadelphia, we are focusing on select posters reporting on studies of ocrelizumab, an intravenous humanised monoclonal antibody that selectively targets…

read more

Latest advances in migraine therapy

3682 2200 Carlotta Foletti, PhD

Migraines are the most common type of primary headache disorders, and triptans – serotonin 5-HT1B/1D receptor agonists originally developed as cranial vasoconstrictors – are the backbone of current acute attack…

read more
Brainwork is supported by unrestricted grants from: